Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged
| Condition(s) | Androgenic Alopecia |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged 18 to 50 years. Sixty participants will be randomized into 2 treatment groups. The 2dDR group will apply 1 gram of topical 2dDR hydrogel once daily to the affected scalp areas for 6 months. The minoxidil group will apply topical minoxidil 5% solution to the affected scalp areas for 6 months according to sex-specific dosing in the protocol. Participants will undergo clinical assessment, trichoscopic evaluation, and standardized scalp photography at baseline, Week 12, and Week |
| Who can participate | Inclusion Criteria: * Adults aged 18 to 50 years. * Male and female patients with androgenetic alopecia. * Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V in males and Ludwig scale I to II in females. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Other types of hair loss, including inflammatory or scarring alopecia. * Psoriasis. * Inflammatory scalp dermatoses. * History of severe systemic disease, including renal, cardiovascular, or hepatic disease. * Chemotherapy during the last 5 years. * Pregnancy. * Lactation. * Bleeding disorders. |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Lead sponsor | Kasr El Aini Hospital |
| Locations | Cairo, Cairo Governorate, Egypt |
| Start date | 2026-01-01 |
| NCT ID | NCT07502976 |
| Official listing | https://clinicaltrials.gov/study/NCT07502976 |